Peer-influenced content. Sources you trust. No registration required. This is HCN.

Blood AdvancesPosttransplantation MRD Monitoring in Patients w. AML by Next-Generation Sequencing Using DTA and Non-DTA Mutations

In this article from Blood Advances highlighted by helpful visual abstracts, two key points are discussed. First, patient-specific next-generation sequencing (NGS)-based measurable residual disease (MRD) monitoring using non-DTA mutations after allogeneic hematopoietic cell transplantation (alloHCT) is independently prognostic for relapse and survival. Second, the kinetics rather than a single time point should be further evaluated when DTA mutations are used for MRD monitoring after alloHCT.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form